KUKJEON PHARMACEUTICAL Co.,Ltd
Financials
Valuation Metrics
KUKJEON PHARMACEUTICAL Co.,Ltd's Market Cap is ₩1136B. At end of 2025 it was ₩1817B. Ranked #1135 of 2,405 in KR market (top 47%), #593 of 1,627 on KOSDAQ (top 36%), #132 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 57%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 113.64B KRW | KR#1,135/2,405 Sec#132/231 |
| Revenue | 134.57B KRW | KR#1,245/2,405 Sec#77/231 |
| Net Income | -2.08B KRW | KR—/2,405 Sec—/231 |
| Total Assets | 189.20B KRW | KR#1,354/2,405 Sec#98/231 |
| Net Assets | 114.00B KRW | KR#1,322/2,405 Sec#104/231 |
| Employees | 175 | KR#1,189/2,405 Sec#98/231 |
| Value | ||
| P/B | 0.99x | KR#1,531/2,405 Sec#95/231 |
| P/S | 0.84x | KR#1,333/2,405 Sec#77/231 |
| EV/EBITDA | 61.60x | KR#1,404/2,405 Sec#94/231 |
| FCF Yield | 6.59% | KR#795/2,405 Sec#39/231 |
| Profitability | ||
| ROE | -1.83% | KR#1,673/2,405 Sec#116/231 |
| ROA | -1.10% | KR#1,683/2,405 Sec#117/231 |
| Op. Margin | 1.68% | KR#1,422/2,405 Sec#100/231 |
| Revenue Growth | -0.37% | KR#1,542/2,405 Sec#153/231 |
| Financial Health | ||
| Debt Ratio | 65.96% | KR#1,163/2,405 Sec#141/231 |
| Total Debt | 39.89B KRW | KR#1,099/2,405 Sec#77/231 |
| FCF | 7.49B KRW | KR#794/2,405 Sec#48/231 |
| Cash | 14.18B KRW | KR#1,476/2,405 Sec#119/231 |
| Current Ratio | 1.47x | KR#1,223/2,405 Sec#132/231 |
| Net Debt/EBITDA | 11.36x | KR#1,260/2,405 Sec#91/231 |
| Dividend | ||
| Div. Yield | 0.88% | KR#1,174/2,405 Sec#69/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -41.99% | KR#1,759/2,405 Sec#148/231 |
| 1M Return | -11.02% | KR#1,252/2,405 Sec#119/231 |
| From 52W High | -65.00% | KR#1,888/2,405 Sec#159/231 |
| 1Y MDD | -67.51% | KR#1,829/2,405 Sec#155/231 |
| Trading | ||
| Volume | 178,203 shares | KR#413/2,405 Sec#42/231 |
| Trading Value | 370.5M KRW | KR#907/2,405 Sec#100/231 |
| Foreign Own. | 1.25% | KR#1,925/2,405 Sec#188/231 |
| Per Share | ||
| EPS | -39 KRW | KR—/2,405 Sec—/231 |
| BPS | 2,112 KRW | KR#2,055/2,405 Sec#171/231 |
Company Info
Kukjun Pharm, established in 1995 and listed on KOSDAQ in 2020, is a chemical total solution company. Utilizing chemical synthesis technology, it produces active pharmaceutical ingredients (APIs), OLED materials, semiconductor materials, and secondary battery electrolyte additives, operating in both pharmaceutical and material business sectors. The company is conducting Phase 1 clinical trials for an Alzheimer's treatment with Shaperon and Phase 3 clinical trials for a combination treatment with TH Pharm, and constructed a factory in Eumseong-gun in 2023 for the commercial production of materials for AI semiconductor processes. Kukjun Pharm is headquartered in Anyang-si, Gyeonggi-do.